[REVISION HISTORY]

Sildenafil potential to inhibit cancer metastasis

Updated 5 times since CLSTR started tracking revisions of this situation.

What changed

2026-07-31 22:04 UTC → 2026-08-01 20:54 UTC · added ~~removed~~

Late‑July 2026 reports from U.S. and Israeli laboratories showed that sildenafil, the active ingredient in Viagra, suppressed metastatic spread in mouse models of breast, lung, colon and prostate cancer by inhibiting PDE5, raising cGMP, and sequestering cholesterol in lysosomes. A follow‑up study from Israel’s Weizmann Institute confirmed the same biochemical pathway and demonstrated that combining sildenafil with statins further reduced metastatic potential in pre‑clinical experiments. An analysis of health‑service records for nearly five million Israeli patients found that cancer patients prescribed sildenafil—especially when co‑prescribed with statins—had better survival outcomes than matched controls. Laboratory work with mouse and human cancer cells showed slower cholesterol transport and reduced cell migration after sildenafil treatment. On 31 July 2026, Weizmann Institute researchers, together with U.S. collaborators, published a retrospective analysis of individuals who had taken sildenafil before cancer diagnosis. The study reaffirmed that PDE5 inhibition raises cGMP and disrupts cholesterol handling in malignant cells, impeding detachment and metastatic seeding. Experiments indicated that the anti‑metastatic effect was amplified when sildenafil was combined with statins. A study released on 30 July 2026 in *Cancer Research*—led by Ayelet Erez and Yarden Ariav—detailed the PDE5‑cGMP‑NPC1 mechanism, showing that elevated cGMP interferes with NPC1‑mediated cholesterol transport, making highly migratory tumor cells especially vulnerable. The paper also reported that retrospective analysis of millions of patient records confirmed higher survival among cancer patients using sildenafil, with an even stronger benefit when statins were co‑administered. On 1 August 2026, the same research team reiterated these findings, noting that the National Cancer Institute highlighted the repurposing approach as promising but stressed that the results remain experimental. All authors ~~stress that~~ continue to call for rigorous clinical trials ~~are needed~~ before ~~repurposing~~ sildenafil could be considered a therapeutic option for ~~oncology use.~~ cancer patients.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.